Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by Massachusetts General Hospital.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Carolyn N. Krasner, MD, Massachusetts General Hospital Identifier:
First received: July 25, 2012
Last updated: January 22, 2014
Last verified: January 2014
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)